SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors
- 1 July 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 20 (9), 1508-1520
- https://doi.org/10.1158/1535-7163.mct-21-0030
Abstract
Advanced peritoneal carcinomatosis including high-grade ovarian cancer has poor prognosis and a poor response rate to current checkpoint inhibitor immunotherapies; thus, there is an unmet need for effective therapeutics that would provide benefit to these patients. Here we present the preclinical development of SENTI-101, a cell preparation of bone-marrow derived mesenchymal stromal (or Stem) cells (MSCs) that are engineered to express two potent immune-modulatory cytokines, IL-12 and IL-21. Intraperitoneal administration of SENTI-101 results in selective tumor-homing and localized and sustained cytokine production in murine models of peritoneal cancer. SENTI-101 has extended half-life, reduced systemic distribution and improved anti-tumor activity when compared to recombinant cytokines, suggesting that it is more effective and has lower risk of systemic immunotoxicities. Treatment of tumor-bearing immune-competent mice with a murine surrogate of SENTI-101 (mSENTI-101) results in a potent and localized immune response consistent with increased number and activation of antigen presenting cells, T cells and B cells, which leads to anti-tumor response and memory-induced long-term immunity. Consistent with this mechanism of action, co-administration of mSENTI-101 with checkpoint inhibitors leads to synergistic improvement in anti-tumor response. Collectively, these data warrant potential clinical development of SENTI-101 for patients with peritoneal carcinomatosis and high-grade ovarian cancer.Other Versions
Funding Information
- nothing to report
This publication has 68 references indexed in Scilit:
- Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient dataAnnals Of Oncology, 2013
- Three-dimensional hMSC motility within peptide-functionalized PEG-based hydrogels of varying adhesivity and crosslinking densityActa Biomaterialia, 2013
- CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian CancerClinical Cancer Research, 2012
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancerGene Therapy, 2009
- Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent ImagingThe International Journal of Cell Cloning, 2009
- Interleukin‐21 activates human natural killer cells and modulates their surface receptor expressionImmunology, 2008
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaJournal of Translational Medicine, 2007
- Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpressionInternational Journal of Cancer, 2004
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003